C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard
-
Jun 29, 2026, 06:25Aliaa Albadri: When a Hair Wash Leads to a Stroke Workup
-
Jun 29, 2026, 06:22Tehreen Parveen: Historical Milestone in Drug Discovery – The Discovery of Aspirin
-
Jun 29, 2026, 06:16Muhammad Sufyan: Deep Vein Thrombosis – Recognizing the Warning Signs
-
Jun 29, 2026, 05:33Janak Sadhu: Uniting for The Stroke-Free Mehsana Initiative
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026
-
Jun 29, 2026, 04:50Scott Cameron: ACC/AHA Guidance on Acute Pulmonary Embolism Management
-
Jun 29, 2026, 03:10Aryabhatta Sadhu: ABO and Rh Incompatibility In Stem Cell Transplantation